Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerization mechanism.
We analyzed the polymerization of BbetaA68T fibrinogen, the recombinant counterpart of fibrinogen Naples, a variant known to have decreased thrombin binding. When polymerized with equal thrombin concentrations, BbetaA68T fibrinogen had a longer lag time and lower rate of lateral aggregation, V(max), than normal recombinant fibrinogen, but a similar final turbidity. At thrombin concentrations that equalized the rates of fibrinopeptide A release, BbetaA68T fibrinogen polymerized with a lag time and V(max) similar to normal, but reached a significantly lower final turbidity. Similar results were produced when BbetaA68T was polymerized with Ancrod, which cleaves fibrinopeptide A at the same rate from either fibrinogen, and when BbetaA68T desA monomers were polymerized. The polymerization of desAB fibrin monomers, which circumvents fibrinopeptide release, was the same for both fibrinogens. We confirmed that turbidity was indicative of fiber thickness by scanning electron microscopy of fibrin clots. Here, we present the first experimental evidence of fibrin polymerization with a normal period of protofibril formation and rate of lateral aggregation, but with a significantly decreased extent of lateral aggregation. We conclude that the decreased lateral aggregation seen in BbetaA68T fibrinogen is due to an altered step in the enzymatic phase of its polymerization process. We propose that during normal polymerization a subtle conformational change in the E domain occurs, between the release of FpA and FpB, and that this change modulates the mechanism of lateral aggregation. Without this change, the lateral aggregation of BbetaA68T fibrinogen is impaired such that variant clots have thinner fibers than normal clots.
Mullin
J L
JL
Department of Chemistry and Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7525, USA.
Gorkun
O V
OV
Lord
S T
ST
D000409:Alanine / Q000235:genetics; D000721:Ancrod / Q000494:pharmacology; D001777:Blood Coagulation; D005337:Fibrin / Q000648:ultrastructure; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000235:genetics / Q000378:metabolism* / Q000648:ultrastructure; D015241:Fibrinogens, Abnormal / Q000235:genetics / Q000378:metabolism* / Q000648:ultrastructure; D014644:Genetic Variation; D011108:Polymers; D011994:Recombinant Proteins / Q000378:metabolism; D013912:Threonine / Q000235:genetics; D013917:Thrombin / Q000494:pharmacology
C115499:BBeta fibrinogen; D005338:Fibrin Fibrinogen Degradation Products; D015241:Fibrinogens, Abnormal; D011108:Polymers; D011994:Recombinant Proteins; C048634:fibrinogen Milano II; D013912:Threonine; D005337:Fibrin; D005340:Fibrinogen; D000721:Ancrod; D013917:Thrombin; D000409:Alanine